Acute encephalomyelitis in a 52-year-old male post messenger ribonucleic acid severe acute respiratory syndrome coronavirus 2 vaccination: a case report

Acute disseminated encephalomyelitis is a well-known, but rare, side effect of some vaccines, or symptom following a febrile illness. A 69-year-old, otherwise healthy Hispanic male presented with acute fever, confusion, and later progressive weakness after receiving the first dose of the mRNA-1273 (...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical case reports 2023-05, Vol.17 (1), p.202-202, Article 202
Main Authors: Alebna, Pamela Lamisi, Shahid, Muhammad Ahmad, Brannan, Timothy, Shen, Ting, Marian, Valentin
Format: Article
Language:English
Subjects:
ADEM
Aged
Analgesics
Biopsy
Care and treatment
Case Report
Case reports
Cerebrospinal fluid
Coronaviruses
Corticosteroids
COVID vaccine
COVID-19
COVID-19 vaccines
Development and progression
Disease
Encephalitis
Encephalomyelitis
Encephalomyelitis - chemically induced
Encephalomyelitis, Acute Disseminated - chemically induced
Fever
Humans
Immunoglobulins
Immunosuppressive agents
Laboratories
Leukocytes
Magnetic resonance imaging
Male
Messenger RNA
Metabolism
Middle Aged
Myelitis
Nervous system
Proteins
RNA - therapeutic use
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Steroids
Urinalysis
Urinary tract infections
Vaccination
Vaccine adverse effects
Vaccines - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Acute disseminated encephalomyelitis is a well-known, but rare, side effect of some vaccines, or symptom following a febrile illness. A 69-year-old, otherwise healthy Hispanic male presented with acute fever, confusion, and later progressive weakness after receiving the first dose of the mRNA-1273 (Moderna) severe acute respiratory syndrome coronavirus 2 vaccine. Considering the progressive deterioration of the patient, despite being on multiple immunosuppressive agents, a brain biopsy was obtained, which revealed nonspecific meningoencephalitis. In this case, we highlight the need for a regulatory framework to assist clinicians and patients with coverage of treatment for acute disseminated encephalomyelitis. The use of intravenous immunoglobulin in conjunction with glucocorticoids seems to be an effective treatment option.
ISSN:1752-1947
1752-1947
DOI:10.1186/s13256-023-03831-2